Matthew Campbell, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on an Phase II study (NCT03370718) exploring the role of cabozantinib, a tyrosine kinase inhibitor, in adrenocortical carcinoma (ACC) management. 18 patients were enrolled with advanced ACC, with the primary endpoint being progression-free survival (PFS) at 4 months (PFS4). The median follow-up was 19.4 months and the PFS4 was 72%, median PFS was 7.2 months. 16 patients had restaging with ORR including 2 partial response, 12 stable disease, and 2 progressive disease as best response; disease control rate was 78%. The median PFS was 7.2 months and median OS was 23.9 months. Overall, cabozantinib was shown to be able to provide sustained disease control in patients with advanced ACC and a manageable safety profile in the majority of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

0 Comments

Up next

Autoplay

Degarelix: A New Treatment for Advanced Prostate Cancer

1 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

Cabozantinib demonstrates disease control in advanced adrenocortical carcinoma

Up next

Language